Mitsubishi UFJ Trust & Banking Corp Sells 14,255 Shares of Hologic, Inc. $HOLX

Mitsubishi UFJ Trust & Banking Corp trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.9% in the 3rd quarter, Holdings Channel reports. The firm owned 349,061 shares of the medical equipment provider’s stock after selling 14,255 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Hologic were worth $23,558,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Invesco Ltd. grew its stake in shares of Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after purchasing an additional 3,505,828 shares during the period. K.J. Harrison & Partners Inc bought a new stake in Hologic during the second quarter valued at approximately $1,987,000. Aberdeen Group plc grew its position in Hologic by 2.8% during the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock valued at $15,964,000 after buying an additional 6,589 shares during the period. Nordea Investment Management AB increased its holdings in Hologic by 7.2% during the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after buying an additional 174,828 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in Hologic in the third quarter worth approximately $4,170,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on HOLX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Morgan Stanley raised their price objective on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $79.31.

Hologic Stock Performance

NASDAQ:HOLX opened at $75.19 on Tuesday. The stock has a 50-day moving average price of $74.82 and a 200 day moving average price of $70.66. The stock has a market capitalization of $16.76 billion, a P/E ratio of 30.32, a P/E/G ratio of 2.13 and a beta of 0.69. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.34. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.01 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.